(Q37030800)

17 August 2017

1 reference

title

Emerging therapies for malignant glioma (English)

1 reference

17 August 2017

Adrienne Boire

2

0 references

author name string

Rimas V Lukas

series ordinal

1

1 reference

17 August 2017

M Kelly Nicholas

series ordinal

3

1 reference

17 August 2017

publication date

1 December 2007

1 reference

Expert Review of Anticancer Therapy

17 August 2017

published in

1 reference

17 August 2017

volume

7

1 reference

17 August 2017

issue

12 Suppl

1 reference

17 August 2017

page(s)

S29-36

1 reference

Epidermal growth factor receptor - mediated signal transduction in the development and therapy of gliomas

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12S.S29

The mammalian target of rapamycin pathway as a potential target for cancer chemoprevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12S.S29

PTEN: its deregulation and tumorigenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12S.S29

Inhibition of Ras and related G-proteins as a therapeutic strategy for blocking malignant glioma growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12S.S29

Histone deacetylase inhibitors: molecular mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12S.S29

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12S.S29

Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12S.S29

Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12S.S29

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12S.S29

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12S.S29

PTEN-mediated resistance to epidermal growth factor receptor kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12S.S29

Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3: report from a phase I/II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12S.S29

Treatment of primary glioblastoma multiforme with cetuximab, radiotherapy and temozolomide (GERT)--phase I/II trial: study protocol

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12S.S29

Use of monoclonal anti-EGFR antibody in the radioimmunotherapy of malignant gliomas in the context of EGFR expression in grade III and IV tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12S.S29

Radioiodinated (I-125) monoclonal antibody 425 in the treatment of high grade glioma patients: ten-year synopsis of a novel treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12S.S29

Radioimmunotherapy as a novel treatment regimen: 125I-labeled monoclonal antibody 425 in the treatment of high-grade brain gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12S.S29

Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12S.S29

Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12S.S29

Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12S.S29

Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12S.S29

A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12S.S29

Use of APO2L/TRAIL with mTOR inhibitors in the treatment of glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12S.S29

The epigenomics of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12S.S29

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12S.S29

MGMT methylation status: the advent of stratified therapy in glioblastoma?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12S.S29

CD81, a cell cycle regulator, is a novel target for histone deacetylase inhibition in glioma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12S.S29

HDAC inhibitors: clinical update and mechanism-based potential.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12S.S29

Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12S.S29

In vivo efficacy of a novel histone deacetylase inhibitor in combination with radiation for the treatment of gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12S.S29

Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12S.S29

Phase I trial of tipifarnib in patients with recurrent malignant glioma taking enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12S.S29

Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12S.S29

Farnesyltransferase inhibitor, R115777, reverses the resistance of human glioma cell lines to ionizing radiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12S.S29

Phase I trial of tipifarnib (R115777) concurrent with radiotherapy in patients with glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12S.S29

Tumor angiogenesis: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12S.S29

Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12S.S29

Angiogenesis in malignant glioma--a target for antitumor therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12S.S29

Further characterization of malignant glioma-derived vascular permeability factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12S.S29

Expression of vascular endothelial growth factor (VEGF) and its receptors (Flt-1 and Flk-1) following permanent and transient occlusion of the middle cerebral artery in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12S.S29

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12S.S29

Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12S.S29

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12S.S29

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12S.S29

Cooperative antitumor effect of multitargeted kinase inhibitor ZD6474 and ionizing radiation in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12S.S29

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12S.S29

Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12S.S29

alpha v-Integrin antagonist EMD 121974 induces apoptosis in brain tumor cells growing on vitronectin and tenascin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12S.S29

Lessons learned in the development of targeted therapy for malignant gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12S.S29

10.1586/14737140.7.12S.S29

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference